# A Study of BL-M07D1 With or Without Pertuzumab Versus Taxane + Trastuzumab and Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer

> **NCT06891833** · PHASE2,PHASE3 · RECRUITING · sponsor: **Sichuan Baili Pharmaceutical Co., Ltd.** · enrollment: 120 (estimated)

## Conditions studied

- HER2-positive Breast Cancer

## Interventions

- **DRUG:** BL-M07D1
- **DRUG:** Pertuzumab

## Key facts

- **NCT ID:** NCT06891833
- **Lead sponsor:** Sichuan Baili Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-05
- **Primary completion:** 2028-12
- **Final completion:** 2028-12
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-10-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06891833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06891833, "A Study of BL-M07D1 With or Without Pertuzumab Versus Taxane + Trastuzumab and Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06891833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*